1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Sir Andrew Witty
|
b)
|
Position/status
|
Chief Executive Officer
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's
ShareReward Plan
|
c)
|
Price(s)
and volume(s)
|
Price(s)Volume(s)£14.77778 (partnership shares)£14.77778
(matching shares)
|
d)
|
Aggregated
information
Aggregated
volume Price
|
16 Ordinary Shares
£14.7777
|
e)
|
Date
of the transaction
|
2016-12-09
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Ms E Walmsley
|
b)
|
Position/status
|
CEO Designate
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's
ShareReward Plan
|
c)
|
Price(s)
and volume(s)
|
Price(s)Volume(s)£14.77779 (partnership shares)£14.77779
(matching shares)
|
d)
|
Aggregated
information
Aggregated
volume Price
|
18 Ordinary Shares
£14.7777
|
e)
|
Date
of the transaction
|
2016-12-09
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Mr R G Connor
|
b)
|
Position/status
|
President, Global Manufacturing & Supply
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's
ShareReward Plan
|
c)
|
Price(s)
and volume(s)
|
Price(s)Volume(s)£14.77778 (partnership shares)£14.77778
(matching shares)
|
d)
|
Aggregated
information
Aggregated
volume Price
|
16 Ordinary Shares
£14.7777
|
e)
|
Date
of the transaction
|
2016-12-09
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Mr S Dingemans
|
b)
|
Position/status
|
Chief Financial Officer
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's
ShareReward Plan
|
c)
|
Price(s)
and volume(s)
|
Price(s)Volume(s)£14.77778 (partnership shares)£14.77778
(matching shares)
|
d)
|
Aggregated
information
Aggregated
volume Price
|
16 Ordinary Shares
£14.7777
|
e)
|
Date
of the transaction
|
2016-12-09
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Mr N Hirons
|
b)
|
Position/status
|
SVP, Global Ethics & Compliance
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's
ShareReward Plan
|
c)
|
Price(s)
and volume(s)
|
Price(s)Volume(s)£14.77779 (partnership shares)£14.77779
(matching shares)
|
d)
|
Aggregated
information
Aggregated
volume Price
|
18 Ordinary Shares
£14.7777
|
e)
|
Date
of the transaction
|
2016-12-09
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Mr S A Hussain
|
b)
|
Position/status
|
President, Global Pharmaceuticals
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's ShareReward
Plan
|
c)
|
Price(s)
and volume(s)
|
Price(s)Volume(s)£14.77778 (partnership shares)£14.77778
(matching shares)
|
d)
|
Aggregated
information
Aggregated
volume Price
|
16 Ordinary Shares
£14.7777
|
e)
|
Date
of the transaction
|
2016-12-09
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Mr D S Redfern
|
b)
|
Position/status
|
Chief Strategy Officer
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's
ShareReward Plan
|
c)
|
Price(s)
and volume(s)
|
Price(s)Volume(s)£14.77778 (partnership shares)£14.77778
(matching shares)
|
d)
|
Aggregated
information
Aggregated
volume Price
|
16 Ordinary Shares
£14.7777
|
e)
|
Date
of the transaction
|
2016-12-09
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Ms C Thomas
|
b)
|
Position/status
|
SVP, Human Resources
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's
ShareReward Plan
|
c)
|
Price(s)
and volume(s)
|
Price(s)Volume(s)£14.77778 (partnership shares)£14.77778
(matching shares)
|
d)
|
Aggregated
information
Aggregated
volume Price
|
16 Ordinary Shares
£14.7777
|
e)
|
Date
of the transaction
|
2016-12-09
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Mr P C Thomson
|
b)
|
Position/status
|
SVP, Communications & Government Affairs
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's
ShareReward Plan
|
c)
|
Price(s)
and volume(s)
|
Price(s)Volume(s)£14.77778 (partnership shares)£14.77778
(matching shares)
|
d)
|
Aggregated
information
Aggregated
volume Price
|
16 Ordinary Shares
£14.7777
|
e)
|
Date
of the transaction
|
2016-12-09
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Dr P J T Vallance
|
b)
|
Position/status
|
President, Pharmaceuticals R&D
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's
ShareReward Plan
|
c)
|
Price(s)
and volume(s)
|
Price(s)Volume(s)£14.77779 (partnership shares)£14.77779
(matching shares)
|
d)
|
Aggregated
information
Aggregated
volume Price
|
18 Ordinary Shares
£14.7777
|
e)
|
Date
of the transaction
|
2016-12-09
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Mrs V A Whyte
|
b)
|
Position/status
|
Company Secretary
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's
ShareReward Plan
|
c)
|
Price(s)
and volume(s)
|
Price(s)Volume(s)£14.77778 (partnership shares)£14.77778
(matching shares)
|
d)
|
Aggregated
information
Aggregated
volume Price
|
16 Ordinary Shares
£14.7777
|
e)
|
Date
of the transaction
|
2016-12-09
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
GlaxoSmithKline plc
|
|
(Registrant)
|
|
|
Date: December
12, 2016
|
|
|
|
|
By: VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GlaxoSmithKline plc
|